Bio-Rad Laboratories, Inc. (CA, USA) recently launched its ddPCR Microsatellite Instability (MSI) Assay, which detects instability in the genome that makes people susceptible to colorectal cancer and signals that they’re eligible for immune checkpoint inhibitor therapy.
Bio-Rad’s Droplet Digital PCR (ddPCR) Microsatellite Instability (MSI) RUO Assay is available for early access customers. The ddPCR MSI assay can be completed in one day on a ddPCR-based platform to quantify the level of MSI present in colorectal tumors. Using either a blood or FFPE sample, the assay quantitatively identifies mutations in five loci that lead to identification of MSI status. Colorectal tumors that test positive for MSI-high are candidates for treatment with immune-checkpoint inhibitors. Bio-Rad’s assay is simple, highly sensitive and provides a standardized output that does not require a pathologist’s interpretation. The test can use patient blood samples in the absence of tumor tissue and does not require matched normal tissue or normal blood samples. Visit our website for more information.
For research use only. Not for use in diagnostic procedures.
Updated 9 August, 2019